JPMorgan Chase & Co. Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $74.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target decreased by JPMorgan Chase & Co. from $120.00 to $74.00 in a research report report published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Jefferies Financial Group lowered their target price on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Canaccord Genuity Group reduced their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Barclays decreased their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, November 24th. Wells Fargo & Company lowered their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.76.

Ultragenyx Pharmaceutical Stock Down 1.7%

Shares of NASDAQ:RARE opened at $21.34 on Thursday. The company’s 50-day moving average price is $23.01 and its 200 day moving average price is $28.82. The company has a market cap of $2.06 billion, a PE ratio of -3.65 and a beta of 0.16. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same quarter last year, the company posted ($1.39) EPS. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the sale, the executive vice president owned 76,346 shares in the company, valued at $1,740,688.80. This represents a 9.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Emil D. Kakkis sold 54,404 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at $15,025,063.20. This represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 104,958 shares of company stock worth $2,394,858. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently added to or reduced their stakes in RARE. Assetmark Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank raised its position in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at $39,000. Smartleaf Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.